AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
about
Axitinib for the management of metastatic renal cell carcinomaSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesMultikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinibProfile of trebananib (AMG386) and its potential in the treatment of ovarian cancerc-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutationsA phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.Sphingosine kinase activity is not required for tumor cell viabilitySimulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.Thyroid cancer: current molecular perspectives.Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapyAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery.Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experienceStructure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).Multikinase inhibitors use in differentiated thyroid carcinoma.Angiogenesis modulates adipogenesis and obesity.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceAntiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer.A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLCDifferentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.Targeted treatment of differentiated and medullary thyroid cancer.Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.New therapies for dedifferentiated papillary thyroid cancerDiagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.Standard and emerging therapies for metastatic differentiated thyroid cancer.New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyondDifferentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancerAdding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancerMechanisms and Targets Involved in Dissemination of Ovarian Cancer.
P2860
Q24613720-FD068D60-F6EF-4895-A916-4541FF0DB4B6Q26751274-8C457C9C-5AFB-4DF1-B4AE-E7F4F8E26DF6Q26821959-FF0F61AB-B8EA-49B6-83DE-5ABF394F50C2Q26991997-D6E39261-2033-4769-9F47-0391726802E7Q27649203-92A92F86-1239-4265-8814-1A96915F512EQ30414010-DE4C8748-6840-4BDC-95AA-CB30E2722161Q30452205-12BEF395-405F-4E18-BF07-DDA7E754146CQ30558610-92CECF0E-F7DD-497C-8CA2-D9CC511E576AQ33732486-70B324FB-E285-470C-915E-784B768FE363Q33760910-D84FEC77-10BA-455C-B6B9-E9669927908AQ33972047-2016D5E4-4FE0-4808-815F-D8B07A256406Q34031293-12B4939F-EE70-4706-BA85-D02881CE2EE6Q34046157-37748B15-ED63-4DB7-9152-4404ACBD1FF9Q34068827-B8DDD84D-33FE-4916-A796-ED03BFD68F57Q34088265-CD453AE3-F5B5-4985-BC7C-08A3A42A9F69Q34094154-7002BE46-1F09-4096-AB48-3AF076D0D4EEQ34337865-D9854E87-1783-4F2E-8ED6-65799A673B52Q34517849-65136E37-92C9-489C-96FF-E7B68586D721Q34660901-B9CC0E1D-F344-4AAC-B3FF-B9D838A0E1FEQ34677131-B88E80BA-11EA-486B-8304-56E5F34640F4Q34774854-D25C0BF1-EE7B-49C1-9C70-01A25F77D7F9Q34862792-3508C856-ECBF-4A6D-BA78-7092C5AB14C9Q34923902-587241B5-94C4-4A07-BEE6-CBE5279DCE97Q34956830-47158849-136D-4DB1-BF22-3EA3C6448759Q35050210-C901AF1D-DF91-4349-811D-8C3878C8645DQ35057314-25F29E13-9D24-48A3-BCFA-C283D1E08D49Q35069657-553D550B-2310-4980-9802-053C5C716CA4Q35147151-4DF73A5A-3DBD-4F7F-A5C3-EF64A54EB07EQ35233993-AFA82011-7DCC-4BFB-9868-E48A9A1ADC3BQ35381593-5D2FD58C-17A7-40A0-815E-DE83282A72DAQ35396089-A20D93FF-29AA-45FB-BD6E-6006B5015B2EQ35525772-732E352F-497B-4804-A246-41C3A5D42838Q35550182-F884AE7E-9FAC-4C06-9E9E-694371C08ED4Q35583906-E94B6319-0A53-4D4F-922D-47E0D29DAE25Q35660763-7AF59696-D1CE-4D3C-A7B4-CB563EA28869Q35864072-9C38395B-58C1-4D03-9E85-8E27777134DCQ35954103-46D45D41-6132-48EB-B309-4499098F16B2Q36147155-13E8960C-6BD3-42A2-A15F-A555AF9B14D7Q36161541-5A235D70-44BD-4F9F-98B4-0580E642970EQ36180735-4DD1A4AD-87D1-43BA-A1C7-1296D42B7C63
P2860
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@ast
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@en
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@nl
type
label
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@ast
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@en
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@nl
prefLabel
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@ast
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@en
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@nl
P2093
P1433
P1476
AMG 706, an oral, multikinase ...... egression in tumor xenografts.
@en
P2093
Andrew Tasker
Angela Coxon
Anthony Polverino
Charlie Starnes
Danlin Chen
Gondi Kumar
Gonzalo Alva
James Bready
James Meyer
Jane Talvenheimo
P304
P356
10.1158/0008-5472.CAN-05-4665
P407
P577
2006-09-01T00:00:00Z